Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)

v3.26.1
Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Deferred tax assets:    
Net operating losses carry forward $ 62,548 $ 47,875
Deferred revenue 8,546 8,217
Share-based compensation 14 1,572
Research and development/orphan drug credits 24,811 23,296
Capitalized research and development expenses 20,131 20,664
Lease liabilities 414 369
Others 44 20
Total gross deferred tax assets 116,508 102,013
Less: valuation allowance (116,077) (101,613)
Deferred tax assets, net 431 400
Deferred tax liabilities:    
Lease right-of-use assets (431) (400)
Total gross deferred tax assets (431) (400)
Deferred tax assets, net